Filtered By:
Drug: Norvasc
Nutrition: Calcium
This page shows you your search results in order of date.
Order by Relevance | Date
Total 20 results found since Jan 2013.
Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension
RARITAN, NJ, November 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Idorsia Ltd, today announced results from the Phase 3 PRECISION study, which found aprocitentan, an investigational, novel dual endothelin receptor antagonist (ERA), significantly reduced blood pressure (BP) and maintained the effect for up to 48 weeks when added to standardized combination background antihypertensive therapy in patients with difficult-to-control hypertension (sometimes referred to as resistant hypertension). These data were presented as a Late-Breaking Science presentation during the Amer...
Source: Johnson and Johnson - November 7, 2022 Category: Pharmaceuticals Source Type: news
Effect of Amlodipine in Stroke and Myocardial infarction: A Systematic Review and Meta-analysis
ConclusionIn the pooled analysis of data from 12 randomised controlled trials and one double-blinded cohort study measuring the effect of CCBs, we found that the CCB amlodipine reduced the risk of stroke and MI in hypertensive patients. Superior results for amlodipine were found in ten of the 13 studies included in this meta-analysis.
Source: Cardiology and Therapy - September 4, 2021 Category: Cardiology Source Type: research
Cardiovascular Benefits of Angiotensin Converting Enzyme Inhibition plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and with Resistant Hypertension.
CONCLUSIONS: Combination therapy adding a calcium channel blocker, rather than hydrochlorothiazide, to an angiotensin converting enzyme inhibitor was more effective in preventing composite cardiovascular events even in hypertensive patients achieving aggressive systolic blood pressure targets as well as in those with apparent resistant hypertension. Our findings add support that most patients, including those following contemporary clinical guidelines, will benefit from this combination.
TRIAL REGISTRATION: ClinicalTrials.gov, NCT00170950.
PMID: 33216879 [PubMed - as supplied by publisher]
Source: American Journal of Hypertension - November 20, 2020 Category: Cardiology Authors: Brook RD, Kaciroti N, Bakris G, Dahlöf B, Pitt B, Velazquez E, Weber MA, Jamerson KA, ACCOMPLISH investigators Tags: Am J Hypertens Source Type: research
Role of TREK-1 in Health and Disease, Focus on the Central Nervous System
Conclusion and Perspectives
Since their cloning 20 years ago, the physiological importance of TREK-1 channels has continued to grow (Figure 3). Today, TREK-1 channels have been shown to be important and their presence is essential in a number of physiopathological processes. Their involvement in these different processes demonstrate the necessity to design pharmacological modulators, activators or inhibitors, of these channels to correct any TREK-1-related dysfunctions.
Despites a number of studies and many molecule screenings, only few putative new drugs were identified. The activators belonging to the ML and BL series ...
Source: Frontiers in Pharmacology - April 10, 2019 Category: Drugs & Pharmacology Source Type: research
Benefits May Persist After Antihypertensive and Statin Treatment
Patients with hypertension may benefit from antihypertensive treatment with a calcium channel blocker and a lipid-lowering statin years after taking the medications, reported a long-term follow-upstudy in theLancet. Patients who received amlodipine-based antihypertensive treatment had fewer stroke deaths —independent of blood pressure levels—and patients taking lipid-lowering atorvastatin had fewer cardiovascular deaths.
Source: JAMA - October 23, 2018 Category: General Medicine Source Type: research
Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial
Publication date: Available online 26 August 2018Source: The LancetAuthor(s): Ajay Gupta, Judith Mackay, Andrew Whitehouse, Thomas Godec, Tim Collier, Stuart Pocock, Neil Poulter, Peter SeverSummaryBackgroundIn patients with hypertension, the long-term cardiovascular and all-cause mortality effects of different blood pressure-lowering regimens and lipid-lowering treatment are not well documented, particularly in clinical trial settings. The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy Study reports mortality outcomes after 16 years of follow-up of the UK participants in the original ASCOT trial.MethodsASCOT was...
Source: The Lancet - August 26, 2018 Category: General Medicine Source Type: research
Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT.
CONCLUSIONS: AF/AFL is a significant risk factor for stroke, HF, and mortality. Additional risk factors for these outcomes were generally similar for participants with and without baseline or incident AF/AFL.
PMID: 30126559 [PubMed - in process]
Source: Journal of the National Medical Association - August 22, 2018 Category: General Medicine Tags: J Natl Med Assoc Source Type: research
Personalised Single-Pill Combination Therapy in Hypertensive Patients: An Update of a Practical Treatment Platform
AbstractDespite the improvements in the management of hypertension during the last three decades, it continues to be one of the leading causes of cardiovascular morbidity and mortality worldwide. Effective and sustained reductions in blood pressure (BP) reduce the incidence of myocardial infarction, stroke, congestive heart failure and cardiovascular death. However, the proportion of patients who achieve the recommended BP goal (< 140/90 mmHg) is persistently low, worldwide. Poor adherence to therapy, complex therapeutic regimens, clinical inertia, drug-related adverse events and multiple risk factors or comorbiditie...
Source: High Blood Pressure and Cardiovascular Prevention - October 31, 2017 Category: Cardiology Source Type: research
Abstract P480: Effects Of Long And Intermediate Acting Dihydropyridine Calcium Channel Blockers In Hypertension: A Systematic Review And Aeta-analysis Of 18 Prospective, Actively Controlled, Randomized Clinical Trials Session Title: Antihypertensive Drugs and Pharmacology, Patient-Provider-Healthcare System Issues, and Pediatric and Adolescent Hypertension
Conclusions: This study suggests that Amlodipine offers greater protection against major complications of hypertension compared to intermediate acting dihydropyridine calcium channel blockers.
Source: Hypertension - September 14, 2017 Category: Cardiology Authors: Sandip Chaugai, Hisatomi Arima, Lhamo Yangchen Sherpa, Amir Sepehry Tags: Poster Abstract Presentations Source Type: research
Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control
AbstractRecent epidemiological surveys have demonstrated that effective and sustained blood pressure (BP) control is achieved in a relatively small proportion of treated hypertensive patients. Indeed, treatment of hypertension represents a key strategy for preventing coronary artery disease, stroke, congestive heart failure and cardiovascular death. Several interventions have been proposed by international guidelines for ameliorating hypertension management and control, mostly including integrated and multi-dimensional pharmacological and non-pharmacological strategies. In particular, numerous evidence demonstrated that a ...
Source: High Blood Pressure and Cardiovascular Prevention - June 12, 2017 Category: Cardiology Source Type: research
Long-term outcomes of lercanidipine versus other calcium channel blockers in newly-diagnosed hypertension: a nationwide cohort study.
CONCLUSION: In newly diagnosed patients with hypertension, lercanidipine was superior than nifedipine in the six-year period when the analyzed endpoint was stroke.
PMID: 28300435 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - March 19, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research
Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study
In this study, 5857 patients received coprescription of CYP3A4-metabolized statins and CCBs that inhibit CYP3A4. There were no differences in comorbidity or use of antihypertensive drugs between patients who received CYP3A4-metabolized statins and those who received non-CYP3A4-metabolized statins. Patients who received CYP3A4-metabolized statins had significantly higher risk of acute kidney injury (adjusted odds ratio [OR] = 2.12; 95% CI = 1.35–3.35), hyperkalemia (adjusted OR = 2.94; 95% CI = 1.36–6.35), acute myocardial infarction (adjusted OR = 1.55; 95% CI = 1.16–2.07), and acute ischemic ...
Source: Medicine - January 1, 2016 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
A Systematic Review on the Efficacy of Amlodipine in the Treatment of Patients With Hypertension With Concomitant Diabetes Mellitus and/or Renal Dysfunction, When Compared With Other Classes of Antihypertensive Medication
The long-term cardiovascular (CV) effects of calcium channel blockers, with special focus on amlodipine, were compared with other classes of antihypertensive medications in high-risk hypertensive patient subgroups. A systematic literature review and meta-analysis was undertaken of 38 unique randomized, active-controlled, parallel-group trials comparing amlodipine/calcium channel blockers with diuretics, β-blockers, α-blockers, angiotensin-converting enzyme inhibitors, or angiotensin II receptor blockers, with ≥6-month follow-up, and which had included assessment of blood pressure (BP) and CV events [all-cause death, CV...
Source: American Journal of Therapeutics - September 1, 2015 Category: Drugs & Pharmacology Tags: Original Articles Source Type: research
Therapy with the Combination of Amlodipine and Irbesartan Has Persistent Preventative Effects on Stroke Onset Associated with BDNF Preservation on Cerebral Vessels in Hypertensive Rats
In this study, we investigated the significant beneficial effects of the combination therapy using amlodipine and irbesartan against stroke onset in hypertensive rats. The animals were fed an 8 % sodium diet and assigned to (1) vehicle, (2) amlodipine (2 mg/kg/day), (3) irbesartan (20 mg/kg/day), and (4) amlodipine + irbesartan groups. The drugs were given orally until 35 days, and incidences of stroke-related signs and mortality and blood pressure (BP) were monitored. Cerebral blood flow (CBF), brain water content, weight of the brain and left ventricle, and histological evaluations were conducted for the treated grou...
Source: Translational Stroke Research - December 23, 2014 Category: Neurology Source Type: research
A Cost Utility Analysis of Amlodipine Compared with Angiotensin II Receptor Blockers in Preventing Stroke and Myocardial Infarction Among Hypertension Patients in the Philippines
Hypertension represents a major health problem, affecting more than 21% of adults in the Philippines. Amlodipine, a calcium channel blocker, is considered to have better tolerance and effectiveness than other classes of antihypertensive treatments. Limited studies have examined the cost-effectiveness of Amlodipine in the Philippines. The purpose of this study was to compare the costs and effectiveness associated with Amlodipine and Angiotensin II Receptor Blockers (Valsartan) in preventing stroke and myocardial infarction (MI) among Filipino hypertension patients.
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: G Encelan-Brizuela, K.Y. Lin, L. Liu Source Type: research
